Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aldeyra Therapeu (NQ: ALDX ) 5.070 -0.180 (-3.43%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Aldeyra Therapeu < Previous 1 2 3 4 5 6 7 8 9 10 Next > Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference June 09, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Why Aldeyra Therapeutics' Shares Are Soaring Today? June 08, 2022 Via Benzinga Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease June 08, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease June 07, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics: Q1 Earnings Insights May 05, 2022 Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease May 24, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference May 23, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness May 18, 2022 Via Benzinga Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness May 18, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study May 05, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights May 05, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting May 04, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire 70 Biggest Movers From Friday May 02, 2022 Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session April 29, 2022 Via Benzinga 48 Stocks Moving In Friday's Mid-Day Session April 29, 2022 Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:... Via Benzinga Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points April 29, 2022 U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday. Via Benzinga The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid April 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session April 29, 2022 Via Benzinga How To Attend Aldeyra Therapeutics Q1 2022 Earnings Conference Call April 29, 2022 Aldeyra Therapeutics (NASDAQ:ALDX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. Via Benzinga Aldeyra Therapeutics Announces Chief Financial Officer Transition April 28, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights April 27, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting April 21, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease April 05, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day March 29, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia March 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More March 27, 2022 Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. Via Benzinga Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022 March 22, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics: Q4 Earnings Insights March 17, 2022 Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... Via Benzinga The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data March 17, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Recap: Aldeyra Therapeutics Q4 Earnings March 17, 2022 Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.